Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors

By T. Hirano, K. Ishihara, M. Hibi. Oncogene, 2000

1,260 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/df3e7d38a89e86f57f12937c18225b074ba5d5f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Karin
2. T. Hirano
3. S. Grivennikov
4. J. O’Shea
5. R. Jove
6. Hua Yu
7. Y. Kanno
8. A. Laurence

In Oncology

1. M. Karin
2. T. Hirano
3. S. Grivennikov
4. R. Jove
5. Hua Yu
6. D. Pardoll
7. J. O’Shea
8. A. Laurence

In Pathology and Forensic Medicine

1. R. Jove
2. M. Karin
3. D. Pardoll
4. Hua Yu
5. T. Hirano
6. F. Powrie
7. M. Sofroniew
8. Jacqueline F. Bromberg

Citations in the corpus

• Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. (2003, background): “However, Stat3 is not ES cellspecific but is found in a variety of other cell types, often associated with differentiation (Hirano et al., 2000).”
• Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. (2007, background): “In addition, other transcription factors, including c-Myc, c-Jun, and c-Fos, are themselves STAT3 targets (Hirano et al. 2000).”
• IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway (2009, background): “IL-17 activates Stat3 via IL-6 induction IL-6 is a Stat3 activator and is elevated in diverse cancers (Hirano et al., 2000).”
• Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis (2010, background): “Direct Involvement of STAT3 in Regulating Cell Survival and Proliferation Genes in CD4+ T Cells STAT3 has been previously implicated in the regulation of genes involved in cell survival and proliferation (Bourillot et al., 2009; Hirano et al., 2000).”
• IL-6 signal transduction and its physiological roles: the signal orchestration model. (2003, background): “2000), multiple myeloma (Kawano et al. 1988; Frassanito et al. 2001; see also reviews in Hirano 1991; Klein et al. 1995; Hirano et al. 2000), and prostate cancer (Smith et al.”
• Role of interleukin-6 in cancer progression and therapeutic resistance (2016, background): “In addition, other transcription factors which promote proliferation, including cMyc, c-Jun and c-Fos, are also targets of STAT-3 [112].”
• The Two Faces of IL-6 in the Tumor Microenvironment (2014, background): “Acting through STAT3, IL-6 also supports tumor cell survival by inducing the expression of anti-apoptotic proteins including bcl2, bcl-XL and survivin [5,20,33,39].”
• STAT proteins: novel molecular targets for cancer drug discovery (2000, background): “…erentiation, proliferation, development, apoptosis, and in¯ammation (Akira, 2000; Bromberg et al., 1996; Cressman et al., 1996; Fukada et al., 1996; Hirano et al., 2000; Kaplan et al., 1996a,b; Planas et al., 1997; Smithgall et al., 2000; Stephens et al., 1996; Takeda et al., 1997; Zhong et al.,…”
• Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. (2014, background): “The JAK family of tyrosine-kinases especially JAK1 mediates the activation of STAT3 [30].”
• Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells (2001, background): “…demonstrated essential functions for STAT proteins in signaling pathways critical to normal cellular processes including immune function, development, di erentiation, proliferation and survival (Akira, 1999, 2000; Dearolf, 1999; Hirano et al., 2000; Levy, 1999; Mui, 1999; Smithgall et al., 2000).”